Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309195 | 0.88 | TP53 (0.53) | S1PR2MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3311088 | 0.87 | S1PR2 (0.56) | S1PR2MAPTTP53 | |
| SCHEMBL3303629 | 0.86 | S1PR2 (0.57) | S1PR2MAPTTP53 | |
| SCHEMBL3309199 | 0.84 | POLB (0.66) | S1PR2MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3313378 | 0.84 | S1PR2 (0.50) | S1PR2MAPTTP53GAAPOLB | |
| SCHEMBL3311661 | 0.81 | S1PR2 (0.84) | S1PR2MAPTSMN1; SMN2TP53POLB | |
| SCHEMBL3312112 | 0.81 | S1PR2 (0.48) | S1PR2MAPTTP53 | |
| SCHEMBL3307499 | 0.78 | SMN1; SMN2 (0.51) | S1PR2MAPTALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3307430 | 0.78 | TP53 (0.48) | MAPTKDM4ESMN1; SMN2TP53 | |
| SCHEMBL13361507 | 0.76 | S1PR2 (0.78) | S1PR2MAPTSMN1; SMN2TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | claimed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | claimed |
| EP-2132186-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | Novartis AG (CH) | 2009-12-16 | — | — | EP | claimed |
| WO-2008107436-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | claimed |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | S1PR2 3/4885MAPT 3853/4885KDM4E 3052/4885 |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | S1PR2 3/4885MAPT 4020/4885KDM4E 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.